argumentA line of reasoning from premises to a conclusion. Like a claim, it belongs to no one who makes it.constitution →

Positive secondary-prevention trials

forThis argument, if it holds, bears in favour of the claim.constitution →Colchicine reduces cardiovascular events in patients with coronary artery disease

The argument

Because COLCOT found low-dose colchicine reduced cardiovascular events after recent myocardial infarction and LoDoCo2 found the same in chronic coronary disease, two large randomized trials spanning the acute and stable ends of coronary artery disease independently observed a benefit, so colchicine reduces cardiovascular events across that spectrum. The case gained regulatory weight when the FDA approved low-dose colchicine for cardiovascular risk reduction in 2023 on the strength of these trials.

Does it work?

Does it follow?: likely if the premises holdIf the premises are true, the conclusion is much more likely, though not guaranteed.constitution →
Do the premises hold?: 2 not separately assessed

If both trials showed real benefit, two independent large randomized trials at opposite ends of the coronary disease spectrum make a true effect much more likely, though they do not guarantee one. The argument rests on COLCOT and LoDoCo2, whose results are not in dispute as reported. Its reach after myocardial infarction is weakened by a conflicting larger trial.

Premises

UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →In the COLCOT trial, low-dose colchicine reduced cardiovascular events after recent myocardial infarction
UnassessedNo current assessment. Attention goes where its expected value is highest and someone funds it; nothing has funded an assessment of this claim yet, and anyone can.constitution →In the LoDoCo2 trial, low-dose colchicine reduced cardiovascular events in chronic coronary disease

Where it is made

Passages where sources make, criticize or mention this argument. They record where it appears, not how strong it is, and none has precedence over another.

No source is recorded as making it.

Earlier ratings

Aug 7, 2026
The inference is sound as far as it goes: two large, independent, placebo-controlled trials covering the acute and stable ends of coronary disease are strong evidence of a real effect. The argument rests on the COLCOT result and the LoDoCo2 result, neither of which is seriously disputed as a trial finding; the caveat is that two positive trials cannot by themselves establish the general claim once a larger trial in an overlapping population has come back null, so the argument establishes a credible case rather than a settled conclusion.